800 related articles for article (PubMed ID: 30339790)
1. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
2. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN
Katewa A; Wang Y; Hackney JA; Huang T; Suto E; Ramamoorthi N; Austin CD; Bremer M; Chen JZ; Crawford JJ; Currie KS; Blomgren P; DeVoss J; DiPaolo JA; Hau J; Johnson A; Lesch J; DeForge LE; Lin Z; Liimatta M; Lubach JW; McVay S; Modrusan Z; Nguyen A; Poon C; Wang J; Liu L; Lee WP; Wong H; Young WB; Townsend MJ; Reif K
JCI Insight; 2017 Apr; 2(7):e90111. PubMed ID: 28405610
[TBL] [Abstract][Full Text] [Related]
3. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
4. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW
Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886
[TBL] [Abstract][Full Text] [Related]
5. BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Chalmers SA; Garcia SJ; Webb D; Herlitz L; Fine J; Klein E; Ramanujam M; Putterman C
Clin Immunol; 2021 Feb; 223():108640. PubMed ID: 33296718
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
7. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
Sugahara K; Maeda Y; Shimano K; Murase M; Mochiduki S; Takemoto K; Kakimoto T; Utsumi H; Oshita K; Kataoka H
J Immunol Res; 2019; 2019():5821589. PubMed ID: 31930150
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
9. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
10. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
[TBL] [Abstract][Full Text] [Related]
12. Regulation of basement membrane-reactive B cells in BXSB, (NZBxNZW)F1, NZB, and MRL/lpr lupus mice.
Clark AG; Fan Q; Brady GF; Mackin KM; Coffman ED; Weston ML; Foster MH
Autoimmunity; 2013 May; 46(3):188-204. PubMed ID: 23157336
[TBL] [Abstract][Full Text] [Related]
13. Intermittent Fasting Aggravates Lupus Nephritis through Increasing Survival and Autophagy of Antibody Secreting Cells in MRL/lpr Mice.
Hong SM; Lee J; Jang SG; Song Y; Kim M; Lee J; Cho ML; Kwok SK; Park SH
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187196
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
15. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
[TBL] [Abstract][Full Text] [Related]
16. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
17. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.
Brightbill HD; Suto E; Blaquiere N; Ramamoorthi N; Sujatha-Bhaskar S; Gogol EB; Castanedo GM; Jackson BT; Kwon YC; Haller S; Lesch J; Bents K; Everett C; Kohli PB; Linge S; Christian L; Barrett K; Jaochico A; Berezhkovskiy LM; Fan PW; Modrusan Z; Veliz K; Townsend MJ; DeVoss J; Johnson AR; Godemann R; Lee WP; Austin CD; McKenzie BS; Hackney JA; Crawford JJ; Staben ST; Alaoui Ismaili MH; Wu LC; Ghilardi N
Nat Commun; 2018 Jan; 9(1):179. PubMed ID: 29330524
[TBL] [Abstract][Full Text] [Related]
18. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.
Grossman TR; Hettrick LA; Johnson RB; Hung G; Peralta R; Watt A; Henry SP; Adamson P; Monia BP; McCaleb ML
Immunobiology; 2016 Jun; 221(6):701-8. PubMed ID: 26307001
[TBL] [Abstract][Full Text] [Related]
20. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]